Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia

Pain

Volumn 126, Issue 1-3, 2006, Pages 54-63

  Miranda, Adrian ^a   Peles, Shachar ^a   McLean, Peter G ^b   Sengupta, Jyoti N ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT3 Receptor; Alosetron; Serotonin; Somatic pain; Visceral hyperalgesia

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST; SODIUM CHLORIDE;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; COLON; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GASTROCNEMIUS MUSCLE; HYPERALGESIA; HYPERSENSITIVITY; INTESTINE DISTENSION; MALE; MECHANOTRANSDUCTION; NONHUMAN; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; RECTUM; SOMATIC PAIN; STATISTICAL SIGNIFICANCE; VISCERAL PAIN; WITHDRAWAL REFLEX;

ABSORPTION; ANIMALS; CARBOLINES; COLON; DILATATION, PATHOLOGIC; ELECTROMYOGRAPHY; GASTROINTESTINAL MOTILITY; HYPERALGESIA; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SPINAL; MALE; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT3; RECTUM; SEROTONIN ANTAGONISTS; VISCERA;

EID: 33751009935     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.06.014     Document Type: Article

References (44)

1. Akkus S., Senol A., Ayvacioglu N.B., Tunc E., Eren I., and Isler M. Is female predominance in irritable bowel syndrome related to fibromyalgia?. Rheumatol Int 24 (2004) 106-109
2. Ali Z., Wu G., Kozlov A., and Barasi S. The role of 5-HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neurosci Lett 208 (1996) 203-207
3. Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., Kong S., Mangel A.W., and Northcutt A.R. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13 (1999) 1149-1159
4. Camilleri M., Northcutt A.R., Kong S., Duke G., McSorley D., and Mangel A. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised, placebo controlled study. Lancet 355 (2000) 1035-1040
5. Camilleri M., Chey W., Mayer E., Northcutt A., Heath A., Dukes G., McSorley D., and Mangel A. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med 161 (2001) 1733-1740
6. Chang L., Ameen V.Z., Dukes G.E., McSorley D.J., Carter E.G., and Mayer E.A. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100 (2005) 115-123
7. Danzebrink R.M., and Gebhart G.F. Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res 538 (1991) 64-75
8. Desmeules J.A., Cedraschi C., Rapiti E., Baumgartner E., Finckh A., Cohen P., Dayer P., and Vischer T.L. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 48 (2003) 1420-1429
9. Eschalier A., Kayser V., and Guilbaud G. Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats. Pain 36 (1989) 249-255
10. Frissora C.L., and Koch K.L. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 7 (2005) 264-271
11. Giordano J., and Gerstmann H. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT3 receptor sensitization. Eur J Pharmacol 483 (2004) 267-269
12. Glaum S.R., Proudfit H.K., and Anderson E.G. Reversal of the antinociceptive effects of intrathecally administered serotonin in the rat by a selective 5-HT3 receptor antagonist. Neurosci Lett 95 (1988) 313-317
13. Glaum S.R., Proudfit H.K., and Anderson E.G. 5-HT3 receptors modulate spinal nociceptive reflexes. Brain Res 510 (1990) 12-16
14. Green G.M., Scarth J., and Dickenson A. An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT(3) receptors in the anaesthetized rat. Pain 89 (2000) 81-88
15. Guilbaud G., Benoist J.M., Eschalier A., Gautron M., and Kayser V. Evidence for peripheral serotonergic mechanisms in the early sensitization after carrageenin-induced inflammation: electrophysiological studies in the ventrobasal complex of the rat thalamus using a potent specific antagonist of peripheral 5-HT receptors. Brain Res 502 (1989) 187-197
16. Hicks G.A., Coldwell J.R., Schindler M., Ward P.A., Jenkins D., Lynn P.A., Humphrey P.P., and Blackshaw L.A. Excitation of rat colonic afferent fibers by 5-HT(3) receptors. J Physiol 544 (2002) 861-869
17. Kilpatrick G.J., Jones B.J., and Tyers M.B. Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159 (1989) 157-164
18. Laporte A.M., Koscielniak T., Ponchant M., Verge D., Hamon M., and Gozlan H. Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands. Synapse 10 (1992) 271-281
19. Lembo T., Wright R.A., Bagby B., Decker C., Gordon S., Jhingran P., and Carter E. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96 (2001) 2662-2670
20. McCleane G.J., Suzuki R., and Dickenson A.H. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double blinded, placebo-controlled cross-over study. Anesth Analg 97 (2003) 1474-1478
21. Mayer E.A., Berman S., Derbyshire S.W., Suyenobu B., Chang L., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., and Naliboff B.D. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16 (2002) 1357-1366
22. Millan M.J. Descending control of pain. Prog Neurobiol 66 (2002) 355-474
23. Miranda A., Peles S., Rudolph C., Shaker R., and Sengupta J.N. Altered visceral sensation in response to somatic pain in the rat. Gastroenterology 126 (2004) 1082-1089
24. Miura M., Lawson D.C., Clary E.M., Mangel A.W., and Pappas T.N. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 44 (1999) 20-24
25. Mori T., Kawano K., and Shishikura T. 5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats. J Pharmacol Sci 94 (2004) 73-76
26. Ness T.J., Metcalf A.M., and Gebhart G.F. A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus. Pain 43 (1990) 377-386
27. Ness T.J., Randich A., and Gebhart G.F. Further behavioral evidence that colorectal distension is a 'noxious' visceral stimulus in rats. Neurosci Lett 131 (1991) 113-116
28. Oyama T., Ueda M., Kuraishi Y., Akaike A., and Satoh M. Dual effect of serotonin on formalin-induced nociception in the rat spinal cord. Neurosci Res 25 (1996) 129-135
29. Rahman W., Suzuki R., Rygh L.J., and Dickenson A.H. Descending serotonergic facilitation mediated through rat spinal 5HT3 receptors is unaltered following carrageenan inflammation. Neurosci Lett 361 (2004) 229-231
30. Peles S., Miranda A., Shaker R., and Sengupta J.N. Acute nociceptive somatic stimulus sensitizes neurones in the spinal cord to colonic distension in the rat. J Physiol 560 (2004) 291-302
31. Prior A., and Read N.W. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 7 (1993) 175-180
32. Richardson B.P., Engel G., Donatsch P., and Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316 (1985) 126-131
33. Sluka K.A., Kalra A., and Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 24 (2001) 37-46
34. Spath M., Stratz T., Neeck G., Kotter I., Hammel B., Amberger C.C., Haus U., Farber L., Pongratz D., and Muller W. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 33 (2004) 267-270
35. Sperber A.D., Atzmon Y., Neumann L., Weisberg I., Shalit Y., Abu-Shakrah M., Fich A., and Buskila D. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 94 (1999) 3541-3546
36. Staud R., Cannon R.C., Mauderli A.P., Robinson M.E., Price D.D., and Vierck Jr. C.J. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 102 (2003) 87-95
37. Stratz T., Farber L., Varga B., Baumgartner C., Haus U., and Muller W. Fibromyalgia treatment with intravenous tropisetron administration. Drugs Exp Clin Res 27 (2001) 113-118
38. Sufka K.J., Schomburg F.M., and Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol Biochem Behav 41 (1992) 53-56
39. Suzuki R., Morcuende S., Webber M., Hunt S.P., and Dickenson A.H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 12 (2002) 1319-1326
40. Triadafilopoulos G., Simms R.W., and Goldenberg D.L. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 36 (1991) 59-64
41. Urban M.O., and Gebhart G.F. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci USA 96 (1999) 7687-7692
42. Veale D., Kavanagh G., Fielding J.F., and Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br J Rheumatol 30 (1991) 220-222
43. Xu W., Qiu X.C., and Han J.S. Serotonin receptor subtypes in spinal antinociception in the rat. J Pharmacol Exp Ther 26 (1994) 1182-1189
44. Zeitz K.P., Guy N., Malmberg A.B., Dirajlal S., Martin W.J., Sun L., Bonhaus D.W., Stucky C.L., Julius D., and Basbaum A.I. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 22 (2002) 1010-1019